← All trials
NCT06067555
Early Phase 1Interventional
Exploratory trials, involving very limited human exposure, with no therapeutic or diagnostic intent (e.g., screening studies, microdose studies).
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2023
- Primary completion
- May 31, 2026
- Completion date
- May 31, 2026
- First posted
- Oct 5, 2023
- Last posted
- Nov 22, 2023
- Enrollment
- 249
- Arms / groups
- 9 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Yale UniversityLead sponsor
- National Institutes of Health (NIH)Collaborator
- Yale UniversityOverall official - principal investigator
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Collaborator
- Silicon Valley Community FoundationCollaborator
- Chan Zuckerberg InitiativeCollaborator
- University of ChicagoCollaborator
- Yale UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.